Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Equity Income (2019 - 2025)

BridgeBio Pharma's Equity Income history spans 3 years, with the latest figure at -$21.0 million for Q4 2025.

  • For Q4 2025, Equity Income fell 25.96% year-over-year to -$21.0 million; the TTM value through Dec 2025 reached -$72.6 million, down 132.84%, while the annual FY2025 figure was -$72.6 million, 132.84% down from the prior year.
  • Equity Income for Q4 2025 was -$21.0 million at BridgeBio Pharma, down from -$15.8 million in the prior quarter.
  • Across five years, Equity Income topped out at -$6.6 million in Q3 2024 and bottomed at -$21.0 million in Q4 2025.